Opendata, web and dolomites

MOBILISE-D SIGNED

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MOBILISE-D" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF NEWCASTLE UPON TYNE 

Organization address
address: KINGS GATE
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU
website: http://www.ncl.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 49˙361˙564 €
 EC max contribution 25˙395˙897 € (51%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) coordinator 3˙856˙400.00
2    ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH DE (STUTTGART) participant 2˙647˙171.00
3    NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU NO (TRONDHEIM) participant 2˙163˙523.00
4    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 2˙094˙841.00
5    FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ES (BARCELONA) participant 1˙597˙781.00
6    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 1˙484˙050.00
7    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 1˙126˙930.00
8    THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV IL (Tel Aviv) participant 1˙117˙625.00
9    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 993˙625.00
10    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 973˙943.00
11    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 855˙665.00
12    FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG DE (ERLANGEN) participant 847˙863.00
13    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 833˙536.00
14    PENUMOLOGISCHES FORSCHUNGSINSTITUTAN DER LUNGENCLINIC GROSSHANSDORF GMBH DE (GROSSHANSDORF) participant 796˙412.00
15    UNIVERSITA VITA-SALUTE SAN RAFFAELE IT (MILANO) participant 705˙980.00
16    MCROBERTS BV NL (S GRAVENHAGE) participant 592˙187.00
17    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) participant 514˙685.00
18    UNIVERSITAT ZURICH CH (ZURICH) participant 511˙875.00
19    IXSCIENT LIMITED UK (TWICKENHAM MIDDLESEX) participant 464˙000.00
20    UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE UK (NEWCASTLE UPON TYNE) participant 434˙135.00
21    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 392˙415.00
22    UNIVERSITA DEGLI STUDI DI SASSARI IT (SASSARI) participant 391˙250.00
23    AMGEN LIMITED UK (CAMBRIDGE) participant 0.00
24    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
25    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
26    ERESEARCH TECHNOLOGY INC US (PHILADELPHIA) participant 0.00
27    GRUNENTHAL GMBH DE (AACHEN) participant 0.00
28    ICON CLINICAL RESEARCH LIMITED IE (DUBLIN) participant 0.00
29    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
30    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
31    PFIZER LIMITED UK (SANDWICH) participant 0.00
32    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
33    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00
34    TEVA PHARMACEUTICAL INDUSTRIES LIMITED IL (PETACH TIVKA) participant 0.00

Map

 Project objective

Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOBILISE-D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOBILISE-D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More